U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
196351196351Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast CancerWithdrawnNo Results AvailableStage IV Breast Cancer|Recurrent Breast CancerDrug: antineoplaston A10|Drug: methotrexate|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: chemotherapy|Procedure: complementary and alternative therapy|Procedure: differentiation therapyhttps://ClinicalTrials.gov/show/NCT00003536
196352196352Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade GliomaActive, not recruitingNo Results AvailableBrain and Central Nervous System TumorsDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003535
196353196353Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate CancerActive, not recruitingNo Results AvailableProstate CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003534
196354196354Antineoplaston Therapy in Treating Patients With Metastatic Prostate CancerActive, not recruitingNo Results AvailableProstate CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003533
196355196355Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian CancerActive, not recruitingNo Results AvailableOvarian CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003532
196356196356Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic CancerActive, not recruitingNo Results AvailablePancreatic CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003531
196357196357Antineoplaston Therapy in Treating Patients With Primary Liver CancerActive, not recruitingNo Results AvailableLiver CancerDrug: antineoplaston A10https://ClinicalTrials.gov/show/NCT00003530
196358196358Raltitrexed in Treating Children With Refractory Acute LeukemiaCompletedNo Results AvailableRecurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid LeukemiaDrug: raltitrexedhttps://ClinicalTrials.gov/show/NCT00003528
196359196359Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary OriginActive, not recruitingNo Results AvailableCarcinoma of Unknown PrimaryDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003526
196360196360Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or VulvaActive, not recruitingNo Results AvailableCervical Cancer|Vulvar CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003525
196361196361Antineoplaston Therapy in Treating Patients With Stomach CancerActive, not recruitingNo Results AvailableGastric CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003524
196362196362Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the PeritoneumCompletedNo Results AvailableOvarian Cancer|Primary Peritoneal Cavity CancerDrug: aminocamptothecin colloidal dispersionhttps://ClinicalTrials.gov/show/NCT00003523
196363196363Antineoplaston Therapy in Treating Patients With Cancer of the Small IntestineActive, not recruitingNo Results AvailableSmall Intestine CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003522
196364196364Antineoplaston Therapy in Treating Patients With Soft Tissue SarcomaActive, not recruitingNo Results AvailableSarcomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003521
196365196365Antineoplaston Therapy in Treating Patients With Stage IV Kidney CancerActive, not recruitingNo Results AvailableKidney Cancer|Transitional Cell Cancer of the Renal Pelvis and UreterDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003520
196366196366Combination Chemotherapy in Treating Women With Breast CancerCompletedNo Results AvailableBreast CancerDrug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloridehttps://ClinicalTrials.gov/show/NCT00003519
196367196367Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell TumorsCompletedNo Results AvailableOvarian Cancer|Testicular Germ Cell TumorDrug: gemcitabine hydrochloride|Drug: paclitaxelhttps://ClinicalTrials.gov/show/NCT00003518
196368196368Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate CancerWithdrawnNo Results AvailableAdenocarcinoma of the Prostate|Stage III Prostate Cancer|Stage IV Prostate Cancer|Recurrent Prostate CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1|Drug: bicalutamide|Drug: flutamide|Drug: leuprolide acetate|Procedure: alternative product therapy|Procedure: antiandrogen therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: complementary and alternative therapy|Procedure: differentiation therapy|Procedure: endocrine therapy|Procedure: hormone therapyhttps://ClinicalTrials.gov/show/NCT00003517
196369196369Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate CancerActive, not recruitingNo Results AvailableProstate CancerDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003516
196370196370Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal TumorsActive, not recruitingNo Results AvailableSarcomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003515
196371196371Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNo Results AvailableMerkel Cell Carcinoma|Islet Cell Carcinoma|Neuroendocrine Carcinoma|Pituitary TumorDrug: antineoplaston A10|Drug: antineoplaston AS2-1|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: complementary and alternative therapy|Procedure: differentiation therapyhttps://ClinicalTrials.gov/show/NCT00003514
196372196372Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory NeuroblastomaActive, not recruitingNo Results AvailableNeuroblastomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003513
196373196373Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's MacroglobulinemiaActive, not recruitingNo Results AvailableLymphoma|Multiple Myeloma and Plasma Cell NeoplasmDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003512
196374196374Antineoplaston Therapy in Treating Patients With Multiple MyelomaActive, not recruitingNo Results AvailableMultiple Myeloma and Plasma Cell NeoplasmDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003511
196375196375Antineoplaston Therapy in Treating Patients With Stage IV MelanomaCompletedNo Results AvailableMelanoma (Skin)Drug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003509
196376196376Antineoplaston Therapy in Treating Patients With Advanced MesotheliomaTerminatedNo Results AvailableMalignant MesotheliomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003508
196377196377Antineoplaston Therapy in Treating Patients With Primary Central Nervous System LymphomaWithdrawnNo Results AvailablePrimary Central Nervous System LymphomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: complementary and alternative therapy|Procedure: differentiation therapyhttps://ClinicalTrials.gov/show/NCT00003505
196378196378Antineoplaston Therapy in Treating Patients With Mantle Cell LymphomaWithdrawnNo Results AvailableContiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma|Recurrent Mantle Cell LymphomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure: cancer prevention intervention|Procedure: complementary and alternative therapy|Procedure: differentiation therapyhttps://ClinicalTrials.gov/show/NCT00003502
196379196379Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaActive, not recruitingNo Results AvailableLymphomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003501
196380196380Antineoplaston Therapy in Treating Patients With Refractory or Recurrent Intermediate-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaActive, not recruitingNo Results AvailableLymphomaDrug: antineoplaston A10|Drug: antineoplaston AS2-1https://ClinicalTrials.gov/show/NCT00003500

* Görseller ve İçerik tekif hakkına sahip olabilir